BC Extra | Apr 8, 2006
Company News

Isis out-licenses ISIS 301012

Late on Friday, ISIS said it out-licensed ISIS 301012 and two preclinical diabetes compounds to Symphony GenIsis. Symphony GenIsis was formed by Symphony Capital, which, along with undisclosed investors, provided an initial investment of $75...
Items per page:
1 - 1 of 1